Monday, 25 Sep 2017

You are here

Obesity Associated with Late-Onset Psoriatic Arthritis

A recent study reports that obesity is linked to late-onset psoriasis and psoriatic arthritis (PsA).  By contrast being of normal weight may be associated with an earlier onset of the disease adn HLA-B27.

Patients with early PsA were compared to those without arthritis (PsC), with regard to their body mass index (BMI) and HLA risk alleles for psoriatic disease (HLA-B*27, B*3901, B*3801, B*0801, B*4402, B*4403, and C*0602). A case-controlled designed was utilized to detect associations. 

Obesity was more common among the 314 patients with early PsA compared to 498 PsC patients (OR 1.77; p = 0.002).

Higher BMI was significantly associated with older age at onset for both PsA and psoriasis (p =  0.009).

HLA-B*27 was higher in patients with normal weight compared with those with higher BMI (p = 0.002).

Body weight significantly influences the onset and expression of psoriatic disease.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Psoriasis Doubles Mortality Risk

Noe and colleagues have reported in the Journal of Investigative Dermatology that by estimating the extent of skin involvement in psoriasis (%BSA) they may assess future mortality risk. 

Psoriasis patients with 10% or more body surface area (BSA) involvement nearly doubled their risk of early death than those without the disease.

IV Golimumab Shines in Psoriatic Arthritis

Golimumab (GOL) is one of five marketed TNF inhibitors (TNFi) that is FDA approved for use in psoriatic arthritis (PsA). PsA approval was based on a 259 patient, randomized, controlled trial wherein GOL treated patients exhibited at week 24 ACR20/50/70 response of 52%, 32%, and 19%, respectively.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Psoriatic Arthritis Patients with Comorbidities have Worse Disease and Poor Responses

A population-based cohort study shows that comorbidities in psoriatic arthritis patients (PsA) were associated with higher disease activity, shorter persistence and reduced clinical response to TNF inhibitors (TNFi). 

FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis

On Thursday, August 3, the FDA Arthritis Advisory Committee (AAC) met to consider tofacitinib for use in patients with psoriatic arthritis. The panel voted 10-1 in favor of approval.